Literature DB >> 26609649

Exploring the association between the Iowa Gambling Task and community functioning in people with schizophrenia.

Paolo Stratta1, Matteo Cella, Gabriella Di Emidio, Alberto Collazzoni, Alessandro Rossi.   

Abstract

BACKGROUND: Decision making (DM) consists of a number of complex processes involving higher-order cognitive functions involved in outcome evaluation. Problems in DM may have significant negative repercussions on community functioning. We hypothesise in individuals with schizophrenia difficulties in community functioning will be associated with DM problems. SUBJECTS AND METHODS: DM performance was assessed using the Iowa Gambling Task (IGT) in 30 individuals with schizophrenia and 32 healthy controls. Participants' choices on the IGT were grouped as: Ambiguous Decisions, where the outcome is uncertain and cannot be predicted (i.e. IGT initial phase), and Risky Decisions, where the outcome can be predicted with an error margin (i.e. IGT final phase). People with schizophrenia were also assessed with measures of community functioning and symptoms.
RESULTS: Controls outperformed individuals with schizophrenia in risky decisions. In patients, levels of community functioning positively correlated with DM performance. Symptomatology was not associated with DM proficiency or functioning.
CONCLUSIONS: DM impairment may represent an important contributor to poor functional outcomes in people with schizophrenia. Interventions targeting decision making and higher order cognitive problems in people with schizophrenia may have a greater impact on functional difficulties.

Entities:  

Mesh:

Year:  2015        PMID: 26609649

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  1 in total

1.  Intermittent Theta Burst Stimulation (iTBS) as an Optimal Treatment for Schizophrenia Risk Decision: an ERSP Study.

Authors:  Yang Wu; Lu Wang; Fengqiong Yu; Gong-Jun Ji; Guixian Xiao; Xu Feifei; Zhu Chunyan; Chen Xingui; Kai Wang
Journal:  Front Psychiatry       Date:  2021-05-10       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.